Helio Costa, Senior Medical Director of Therapeutics and Innovations at Natera, shared Natera’s post on LinkedIn, adding:
“Proud to see our work with NVIDIA Healthcare announced.
This represents an important milestone in scaling multimodal AI foundation models across precision medicine. It builds on foundational work our team began earlier developing proprietary AI genomic foundation models and biomedical agents trained on large-scale, longitudinal, multimodal data spanning DNA, ctDNA, RNA, imaging, clinical records, and outcomes.
The impact goes well beyond diagnostics, supporting smarter biomarker discovery, improved patient stratification, more efficient clinical trial design, and faster development of personalized therapies.
If you’re interested in exploring our capabilities or joining our growing organization, let’s connect.
Huge credit to the teams at Natera and NVIDIA who made this possible. Excited to see how this work continues to shape the future of precision medicine.”
Quoting Natera’s post:
“Together with NVIDIA Healthcare, we are thrilled to announce that we are accelerating the development of our multimodal AI foundation model platform and expanding applications across precision medicine.
By combining Natera’s extensive AI-ready longitudinal data and machine learning with NVIDIA’s compute and software stacks, we can train at unprecedented scale.”
More posts about Natera.